| 27 Apr 2026 |
Jecho Laboratories, Inc. Announces FDA Acceptance of Investigational New Drug (IND) Application for JLM019 for Advanced Malignancies |
| 25 Mar 2026 |
Jecho Laboratories, Inc. to Present Preclinical Oncology Abstract at the 2026 AACR Annual Meeting |
| 16 Mar 2026 |
Jecho Laboratories, Inc. Selected for Pitch Presentation at 16th Annual BioNJ BioPartnering Conference |
| 16 Feb 2026 |
Jecho Laboratories, Inc. Announces Podium Presentation at the BIO Investment and Growth Summit 2026 |
| 19 Jan 2026 |
Jecho Bio Announces First Patient Dosed in Phase 1 Clinical Trial of JLM019 for Advanced Malignancies |
| 14 Nov 2025 |
US FDA Approves Jecho Bio’s Independently Developed Long-Acting IL-15 (JL19001) Injection for Clinical Trials for Non-Muscle-Invasive Bladder Cancer |
| 03 Nov 2025 |
Jecho Laboratories, Inc. Announces Abstract Selected for Poster Presentation at the 16th Annual World ADC Congress |
| 30 Oct 2025 |
Jecho Laboratories, Inc. Announces Late-Breaking Abstract Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting |
| 01 Oct 2025 |
Jecho Biopharmaceuticals Makes Another Breakthrough with Innovative Drug JL19001, Celebrating National Day with a Scientific Milestone |
| 21 Aug 2025 |
Jechobio Receives NMPA IND Clearance for JLM019 for the Treatment of Advanced Malignant Tumors |
| 25 Jun 2025 |
Inside Precision Medicine highlights GPC3-targeting imaging agent to improve liver cancer detection |
| 21 Apr 2025 |
Jechobio Collaborates with Industry Peers to Announce Promising Clinical Data for Innovative GPC-3-Targeted Radionuclide Drug |
| 30 Mar 2025 |
Jecho Laboratories, Inc. Announces Details of Innovative Preclinical Presentations at the 2025 American Association for Cancer (AACR) Annual Meeting |
